Cipla Defeated In US Kyprolis Patent Tussle
Three Key US Patents Not Obvious, Court Finds
Indian firm Cipla went it alone against Amgen and its Onyx Therapeutics subsidiary to obtain a judgment that would allow for market entry in the US for the firm’s generic to the Kyprolis oncology brand. However, a district court has ruled in the main against the firm.
You may also be interested in...
Korean firm Celltrion is aiming to move production of insulin pens inside Korea “for the first time” and break the stranglehold of Big Pharma insulin players in the market by launching a biosimilar product in 2025.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.